文献速递白血病淋巴瘤浆细胞疾病

凋亡的崛起:靶向血液系统恶性肿瘤中的凋亡

The rise of apoptosis: targeting apoptosis in hematologic malignancies.
PubMed 文献 · Blood · 2018-07-16

本文综述了BCL-2家族蛋白在血液系统恶性肿瘤发病机制中的作用,介绍了BH3模拟物的作用机制,概述了靶向促生存蛋白(尤其是BCL-2抑制)的临床数据,讨论了BH3谱分析等功能检测在优先组合和预测应答中的效用,并对未来治疗方案整合提出了展望。

要点

  • BCL-2家族蛋白调控内在凋亡通路,其失调是许多血液系统恶性肿瘤的基础。
  • FDA批准的BCL-2抑制剂维奈克拉在慢性淋巴细胞白血病和部分B细胞非霍奇金淋巴瘤中高效。
  • 维奈克拉对多发性骨髓瘤、急性髓系白血病、骨髓增生异常综合征、急性淋巴细胞白血病等也有临床活性。

核心结论

  • 靶向BCL-2家族促生存蛋白是血液系统恶性肿瘤治疗的重要方向,维奈克拉已在多种血液肿瘤中显示临床活性。

研究设计与样本

  • 综述,介绍BCL-2家族生物学、BH3模拟物作用机制及靶向促生存蛋白的临床数据,重点为BCL-2抑制。

主要发现

  • BCL-2、髓细胞白血病-1和B细胞淋巴瘤-extra large是促生存蛋白,是抗癌治疗的主要靶点,靶向分子处于不同阶段的临床前和临床开发中。
  • FDA批准的BCL-2抑制剂维奈克拉首先在慢性淋巴细胞白血病和部分B细胞非霍奇金淋巴瘤亚型中证明高度有效。
  • 随后发现维奈克拉对多种血液系统恶性肿瘤有临床活性,包括多发性骨髓瘤、急性髓系白血病、骨髓增生异常综合征、急性淋巴细胞白血病等。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dysregulation of the B-cell leukemia/lymphoma-2 (BCL-2) family of proteins of the intrinsic apoptotic pathway is fundamental to the pathophysiology of many hematologic malignancies. The BCL-2 family consists of regulatory proteins that either induce apoptosis (proapoptotic) or inhibit it (prosurvival). BCL-2, myeloid cell leukemia-1, and B-cell lymphoma-extra large are prosurvival proteins that are prime targets for anticancer therapy, and molecules targeting each are in various stages of preclinical and clinical development. The US Food and Drug Administration (FDA)-approved BCL-2 inhibitor venetoclax was first proven to be highly effective in chronic lymphocytic leukemia and some B-cell non-Hodgkin lymphoma subtypes. Subsequently, venetoclax was found to be active clinically against a diverse array of hematologic malignancies including multiple myeloma, acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, and others. Here, we give a brief introduction to BCL-2 family biology and the mechanism of action of BCL-2 Homology 3 (BH3) mimetics, and provide an overview of the clinical data for therapeutically targeting prosurvival proteins in hematologic malignancies, with a focus on BCL-2 inhibition. To prioritize novel agent combinations and predict responders, we discuss the utility of functional assays such as BH3 profiling. Finally, we provide a perspective on how therapies targeting BCL-2 family proteins may be optimally implemented into future therapeutic regimens for hematologic malignancies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Valentin R, Grabow S, Davids MS, et al. The rise of apoptosis: targeting apoptosis in hematologic malignancies. Blood. 2018. PMID: 30012635. doi:10.1182/blood-2018-02-791350

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。